Spectinomycin dihydrochloride pentahydrateSpectinomycin dihydrochloride pentahydrate
MedChemExpress (MCE)
HY-B1828A
22189-32-8
Spectinomycin hydrochloride hydrate
98.0%
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture)
Room temperature in continental US
may vary elsewhere.
Spectinomycin dihydrochloride pentahydrate is a broad-spectrum antibiotic and inhibits the growth of a variety of gram-positive and gram-negative organisms. Spectinomycin dihydrochloride pentahydrate acts by selectively targeting to the bacterial ribosome and interrupting protein synthesis. Spectinomycin dihydrochloride pentahydrate is also a noncompetitive inhibitor of td intron RNA with an Ki value of 7.2 mM-.
Spectinomycin dihydrochloride pentahydrate selectively inhibits protein synthesis in cells and in extracts of Escherichia coli: Spectinomycin dihydrochloride pentahydrate (50 μg/mL) inhibits Escherichia coli growth rapidly and reversibly, and suppresses amino acid incorporation immediately[1]. Spectinomycin dihydrochloride pentahydrate (1 μg/mL or 3 μM) inhibits polypeptide synthesis directed either by endogenous messenger RNA or by MS-2 bacteriophage RNA, with maximum inhibition of 70-80% in extracts of Escherichia coli[1]. Spectinomycin dihydrochloride pentahydrate blocks the translocation of peptidyl-tRNAs from A-site to P-site by inhibiting the binding of elongation factor G to the ribosome[2]. Spectinomycin dihydrochloride pentahydrate interacts specifically with the residues G1064 and 01192 in 16S rRNA and potentially makes it inactive[2]. Spectinomycin dihydrochloride pentahydrate exhibits splicing inhibition and dependent on pH changes and Mg2+ concentration, indicating electrostatic interactions with the intron RNA[3].
Spectinomycin dihydrochloride pentahydrate (20 mg/kg
i.m.
20-100 mg/kg
9 d) shows the safety in healthy chicks[4]. Spectinomycin dihydrochloride pentahydrate (10 mg/kg
i.v.
single dose) has the major elimination pathway by renal excretion, approximately 55% is excreted into the urine in unchanged form[5]. Pharmacokinetics of Spectinomycin dihydrochloride pentahydrate in Rat[5] Parameter C0 (μg/mL) AUC0-∞ (μg?h/mL) Vd (L/kg) CL (L/h/kg) MRT (h) T1/2α (h) T1/2β (h) T1/2γ (h) fe CLrenal (L/h/kg) Eratio Non atrioventricular analysis 44.3 16.8 0.756 0.602 0.757 / / / 0.553 0.359 1.00 Three-compartment model 37.8 15.7 0.747 0.649 1.11 / 0.237 0.754 19.5 / /
bacterial ribosomal subunit[5] In Vitro Spectinomycin dihydrochloride pentahydrate selectively inhibits protein synthesis in cells and in extracts of Escherichia coli: Spectinomycin dihydrochloride pentahydrate (50 μg/mL) inhibits Escherichia coli growth rapidly and reversibly, and suppresses amino acid incorporation immediately[1]. Spectinomycin dihydrochloride pentahydrate (1 μg/mL or 3 μM) inhibits polypeptide synthesis directed either by endogenous messenger RNA or by MS-2 bacteriophage RNA, with maximum inhibition of 70-80% in extracts of Escherichia coli[1]. Spectinomycin dihydrochloride pentahydrate blocks the translocation of peptidyl-tRNAs from A-site to P-site by inhibiting the binding of elongation factor G to the ribosome[2]. Spectinomycin dihydrochloride pentahydrate interacts specifically with the residues G1064 and 01192 in 16S rRNA and potentially makes it inactive[2]. Spectinomycin dihydrochloride pentahydrate exhibits splicing inhibition and dependent on pH changes and Mg2+ concentration, indicating electrostatic interactions with the intron RNA[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Spectinomycin dihydrochloride pentahydrate Related Antibodies
| | | |
| | | | | |
[1]. Davies J, et al. Inhibition of protein synthesis by spectinomycin. Science. 1965 Sep 3
149(3688):1096-8. [Content Brief]
[2]. Brink MF, et al. Spectinomycin interacts specifically with the residues G1064 and C1192 in 16S rRNA, thereby potentially freezing this molecule into an inactive conformation. Nucleic Acids Res. 1994 Feb 11
22(3):325-31. [Content Brief]
[3]. Park IK, et al. Spectinomycin inhibits the self-splicing of the group 1 intron RNA. Biochem Biophys Res Commun. 2000 Mar 16
269(2):574-9. [Content Brief]
[4]. Madhura DB, et al. Pharmacokinetic profile of spectinomycin in rats. Pharmazie. 2013 Aug
68(8):675-6. [Content Brief]
[5]. Khan EA, et al. Safety evaluation study of lincomycin and spectinomycin hydrochloride intramuscular injection in chickens. Toxicol Rep. 2022 Jan 29
9:204-209. [Content Brief]
